Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 176

1.

The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.

Domenger D, Dea D, Theroux L, Moquin L, Gratton A, Poirier J.

Exp Neurol. 2012 Jan;233(1):513-22. doi: 10.1016/j.expneurol.2011.11.031. Epub 2011 Dec 3.

PMID:
22155743
2.

PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.

Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR.

Eur J Neurosci. 2009 Mar;29(5):954-63. doi: 10.1111/j.1460-9568.2009.06657.x. Epub 2009 Feb 24.

PMID:
19245367
3.
5.

The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R.

Curr Pharm Des. 2011;17(5):489-507. Review.

PMID:
21375482
6.
7.

The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice.

Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM.

J Biol Chem. 2005 Jul 8;280(27):25754-9. Epub 2005 May 11.

8.

Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.

Rojo AI, Innamorato NG, Martín-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A.

Glia. 2010 Apr;58(5):588-98. doi: 10.1002/glia.20947.

PMID:
19908287
9.

Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism.

Singh K, Singh S, Singhal NK, Sharma A, Parmar D, Singh MP.

Chem Biol Interact. 2010 Apr 29;185(2):81-93. doi: 10.1016/j.cbi.2010.03.015. Epub 2010 Mar 15.

PMID:
20230807
10.

Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.

Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y.

Eur J Pharm Sci. 2001 Jan;12(3):231-8.

PMID:
11113642
11.

alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.

Bazzu G, Calia G, Puggioni G, Spissu Y, Rocchitta G, Debetto P, Grigoletto J, Zusso M, Migheli R, Serra PA, Desole MS, Miele E.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):482-90. Review.

PMID:
20522009
12.

Chemokines in the MPTP model of Parkinson's disease: absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration.

Kalkonde YV, Morgan WW, Sigala J, Maffi SK, Condello C, Kuziel W, Ahuja SS, Ahuja SK.

Brain Res. 2007 Jan 12;1128(1):1-11. Epub 2006 Nov 28.

PMID:
17126305
13.

Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.

Hsieh MH, Gu SL, Ho SC, Pawlak CR, Lin CL, Ho YJ, Lai TJ, Wu FY.

Behav Brain Res. 2012 Apr 1;229(1):41-7. doi: 10.1016/j.bbr.2011.12.035. Epub 2012 Jan 2.

PMID:
22227506
14.

Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Joniec I, Ciesielska A, Kurkowska-Jastrzebska I, Przybylkowski A, Czlonkowska A, Czlonkowski A.

Brain Res. 2009 Mar 19;1261:7-19. doi: 10.1016/j.brainres.2008.12.081. Epub 2009 Jan 18.

PMID:
19401171
15.

H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.

Koga K, Mori A, Ohashi S, Kurihara N, Kitagawa H, Ishikawa M, Mitsumoto Y, Nakai M.

Eur J Neurosci. 2006 Feb;23(4):1077-81.

PMID:
16519673
16.

Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.

Ookubo M, Yokoyama H, Kato H, Araki T.

Mol Cell Endocrinol. 2009 Nov 13;311(1-2):62-8. doi: 10.1016/j.mce.2009.07.011. Epub 2009 Jul 23.

PMID:
19631714
18.

A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

Kawasaki T, Ago Y, Kitao T, Nashida T, Takagi A, Takuma K, Matsuda T.

Neuropharmacology. 2008 Oct;55(5):654-60. doi: 10.1016/j.neuropharm.2008.05.032. Epub 2008 Jun 5.

PMID:
18573265
20.

Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity.

Choudhury ME, Moritoyo T, Kubo M, Kyaw WT, Yabe H, Nishikawa N, Nagai M, Matsuda S, Nomoto M.

Brain Res. 2011 Apr 12;1384:170-8. doi: 10.1016/j.brainres.2011.02.017. Epub 2011 Mar 5.

PMID:
21320474

Supplemental Content

Support Center